Next Article in Journal
Incidence of Myelotoxicity and Other Adverse Effects Related to Thiopurine Starting in Patients with Inflammatory Bowel Disease: Retrospective Observational Study in a Third-Level Hospital
Previous Article in Journal
Normothermic Ex Situ Machine Perfusion of Vascularized Composite Allografts with Oxygen Microcarriers for 12 Hours Using Real-Time Mitochondrial Redox Quantification
 
 
Article
Peer-Review Record

Iron Chelation in Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms—Real-World Data from the German Noninterventional Study EXCALIBUR

J. Clin. Med. 2023, 12(20), 6569; https://doi.org/10.3390/jcm12206569
by Felicitas Schulz 1,*, Ulrich Hauch 2, Sandra Ketzler-Henkel 3, Eyck von der Heyde 4, Michael Koenigsmann 5, Michael Lauseker 6, Nora Schulte 7 and Ulrich Germing 1
Reviewer 1: Anonymous
Reviewer 2: Anonymous
J. Clin. Med. 2023, 12(20), 6569; https://doi.org/10.3390/jcm12206569
Submission received: 15 September 2023 / Revised: 29 September 2023 / Accepted: 13 October 2023 / Published: 17 October 2023
(This article belongs to the Section Hematology)

Round 1

Reviewer 1 Report

The manuscript investigates the effect of iron chelation in MDS and MPS patients. The authors are to be congratulated for this huge effort. This reviewer has minor comments only:

- Are differences observed between MDS and MPD patients ? this could be discussed in some more details.

- In line with this: are there subgroups benefitting more than others ?

- if so, are thse subgroups charaterized by genetic disease-related abnormalities ?

- can the authors speculate on desitable ferritin levels as a therapeutic goal ?

- what is the trigger to initiate iron chelation? a specific ferritin evel? at the discretion of the treating physician? there may be a huge variation between centers, this bias could be discussed.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

A few issues:

The graphics in the manuscript are relatively unattractive and low-quality, and could be made more hlepful for the readers.

I am concerned with the very large drop-out of patients during control visits (M9, M12, ...). Could the group of patients who stay in observation by biased by their blood counts, transfusion, satisfaction, etc.?

With respect to 'hematological response' -the impact and proportions definitely depends on the composition of MDS subtypes and also on treatment? Also it changes over decades when compared to previous cohorts. 

What about reponse analysis straftified by doseases /interventions?

Lastly, the fact that patients with lower ferritin fare better is a tautology. If they have less transfusions they have milder disease and fare better to begin with.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Round 2

Reviewer 2 Report

I ackowledge the responses provided by the authors. Just the Figures 1 and 3 are there difficult to read, they need improving.

Back to TopTop